This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Mastectomy if no personal history of breast cancer

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Risk-reducing mastectomy for women with no personal history of breast cancer

  • bilateral risk-reducing mastectomy is appropriate only for a small proportion of women who are from high-risk families and should be managed by a multidisciplinary team
    • bilateral mastectomy should be raised as a risk-reducing strategy option with all women at high risk
    • women considering bilateral risk-reducing mastectomy should have genetic counselling in a specialist cancer genetic clinic before a decision is made
    • discuss the risks and benefits of risk reducing mastectomy with women with a known or suspected BRCA1, BRCA2, or TP53 mutation
      • offer women who have BRCA1, BRCA2 or TP53 mutations but who decide against risk-reducing mastectomy, surveillance according to their level of risk
    • pre-operative counselling about psychosocial and sexual consequences of bilateral risk-reducing mastectomy should be undertaken
    • the possibility of breast cancer being diagnosed histologically following a riskreducing mastectomy should be discussed pre-operatively
    • all women considering bilateral risk-reducing mastectomy should be able to discuss their breast reconstruction options (immediate and delayed) with a member of a surgical team with specialist oncoplastic or breast reconstructive skills
    • a surgical team with specialist oncoplastic/breast reconstructive skills should carry out risk-reducing mastectomy and/or reconstruction
    • women considering bilateral risk-reducing mastectomy should be offered access to support groups and/or women who have undergone the procedure

Breast cancer risk category

Near population risk

Moderate risk

High Risk *

Lifetime risk from age 20

Less than 17%

Greater than 17% but less than 30%

30% or greater

Risk between ages 40 and 50

Less than 3%

3-8%

Greater than 8%

*This group includes known BRCA1, BRCA2 and TP53 mutations and rare conditions that carry an increased risk of breast cancer such as Peutz-Jegher syndrome (STK11), Cowden (PTEN) and familial diffuse gastric cancer (E-Cadherin)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.